首页 > 最新文献

Doklady Biochemistry and Biophysics最新文献

英文 中文
Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab 培养基中碱性成纤维细胞生长因子的积累掩盖了抗血管内皮生长因子药物贝伐珠单抗的直接抗肿瘤作用
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924600283
Zhiyong Wang, Ziyi Wang, Liyan Deng, Xiaolan Wu, Yanfang Liang, Pei Wei

The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.

贝伐单抗(BEV)的直接抗肿瘤作用一直存在争议。药物直接抗肿瘤活性的证据主要来自体外实验,而体外实验受实验条件的影响很大。在本研究中,我们评估了含有 BEV 的培养基更新对 A549 和 U251 癌细胞体外细胞毒性实验结果的影响。我们观察到,含 BEV 培养基更新和不含 BEV 培养基更新的实验结果截然不同。具体来说,在及时更换含 BEV 的培养基的情况下,BEV 可抑制肿瘤细胞的生长,但在不更换培养基的情况下,BEV 可促进肿瘤细胞的生长。同时,与对照组相比,未更新培养基组上清液中碱性成纤维细胞生长因子(bFGF)明显累积,而更换培养基组上清液中无累积。此外,在不更新培养基组中,bFGF 中和可部分逆转 BEV 的促增殖作用,而在更新培养基组中,外源性 bFGF 可减轻 BEV 对肿瘤细胞生长的抑制作用。我们的数据从肿瘤细胞代偿性自分泌细胞因子的角度解释了不同研究中对BEV直接抗肿瘤作用的争议。
{"title":"Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab","authors":"Zhiyong Wang,&nbsp;Ziyi Wang,&nbsp;Liyan Deng,&nbsp;Xiaolan Wu,&nbsp;Yanfang Liang,&nbsp;Pei Wei","doi":"10.1134/S1607672924600283","DOIUrl":"10.1134/S1607672924600283","url":null,"abstract":"<p>The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"285 - 290"},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout 痛风患者冠心病的患病率及相关因素
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700972
E. L. Markelova, M. S. Eliseev, E. V. Il’inykh, S. I. Glukhova,  E. L. Nasonov

Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD) and gout deserves careful examination.

. The aim of this study was to determine the prevalence of CHD and factors associated with CHD in patients (pts) with gout.

. The study involved 286 male patients with gout, age 51.2 [42.8; 59.4] years (ys), disease duration 6.2 [3.8; 12.1] ys. All patients underwent standard clinical examination screening traditional risk factors (TRFs) of CVDs. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).

. CHD was found in 111 out of the 286 pts (38.8%), MI had a history in 29.7%. Compared to individuals with CHD, participants without CHD were older (56.7[52.1; 61.1] vs 46.2[40.6; 53.4] ys), had longer duration of gout (9.3[4.7; 15.1] vs 5.6[3.3; 9.7] ys) (for all p < 0.05). Abdominal obesity (OR, 3.6; 95% CI, 1.2–10.9), family history of CHD (OR, 2.2; 95% CI, 1.3–3.7), disease duration of gout more 10 ys (OR, 2.8; 95% CI, 1.6–4.7), age of gout onset < 35 ys (OR, 5.5; 95% CI, 2.6–11.7), intraosseous tophi (OR, 3.03; 95% CI, 1.8–5.01), nephrolithiasis (OR, 1.7; 95% CI, 1.04–3.04), renal failure (OR, 5.6; 95% CI, 2.7–11.4), serum total cholesterol (TC), (OR, 1.6; 95% CI, 1.0–2.8), serum creatinine (OR, 2.5; 95% CI, 1.2–5.1), increased the risk for CHD in patients with a gout.

. The prevalence of CHD was 38.8% among individuals with gout (one-third of patients had a history of MI 29.7%). Our study showed that both TRFs of CVD and the severity of gout and a history of renal failure contribute to the development of CHD in patients with gout.

痛风会增加心血管疾病(CVD)的发病率和死亡率。因此,冠心病(CHD)与痛风之间的关联值得仔细研究。本研究旨在确定痛风患者(pts)中冠心病的患病率以及与冠心病相关的因素。研究涉及 286 名男性痛风患者,年龄 51.2 [42.8; 59.4] 岁,病程 6.2 [3.8; 12.1] 年。所有患者均接受了标准临床检查,筛查了心血管疾病的传统危险因素(TRFs)。我们估算了调整后的几率比(OR)和 95% 置信区间(95% CI)。286名患者中有111人(38.8%)患有冠心病,29.7%的患者有心肌梗死病史。与患有冠心病的患者相比,未患冠心病的患者年龄更大(56.7[52.1; 61.1] vs 46.2[40.6; 53.4]岁),痛风持续时间更长(9.3[4.7; 15.1] vs 5.6[3.3; 9.7]岁)(P均小于0.05)。01)、肾结石(OR,1.7;95% CI,1.04-3.04)、肾功能衰竭(OR,5.6;95% CI,2.7-11.4)、血清总胆固醇(TC)(OR,1.6;95% CI,1.0-2.8)、血清肌酐(OR,2.5;95% CI,1.2-5.1)会增加痛风患者罹患冠心病的风险。痛风患者的冠心病发病率为 38.8%(三分之一的患者有心肌梗死病史,占 29.7%)。我们的研究表明,心血管疾病的TRFs和痛风的严重程度以及肾功能衰竭史都会导致痛风患者罹患冠心病。
{"title":"The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout","authors":"E. L. Markelova,&nbsp;M. S. Eliseev,&nbsp;E. V. Il’inykh,&nbsp;S. I. Glukhova,&nbsp; E. L. Nasonov","doi":"10.1134/S1607672924700972","DOIUrl":"10.1134/S1607672924700972","url":null,"abstract":"<p>Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD) and gout deserves careful examination.</p><p><b>.</b> The aim of this study was to determine the prevalence of CHD and factors associated with CHD in patients (pts) with gout.</p><p><b>.</b> The study involved 286 male patients with gout, age 51.2 [42.8; 59.4] years (ys), disease duration 6.2 [3.8; 12.1] ys. All patients underwent standard clinical examination screening traditional risk factors (TRFs) of CVDs. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).</p><p><b>.</b> CHD was found in 111 out of the 286 pts (38.8%), MI had a history in 29.7%. Compared to individuals with CHD, participants without CHD were older (56.7[52.1; 61.1] vs 46.2[40.6; 53.4] ys), had longer duration of gout (9.3[4.7; 15.1] vs 5.6[3.3; 9.7] ys) (for all <i>p</i> &lt; 0.05). Abdominal obesity (OR, 3.6; 95% CI, 1.2–10.9), family history of CHD (OR, 2.2; 95% CI, 1.3–3.7), disease duration of gout more 10 ys (OR, 2.8; 95% CI, 1.6–4.7), age of gout onset &lt; 35 ys (OR, 5.5; 95% CI, 2.6–11.7), intraosseous tophi (OR, 3.03; 95% CI, 1.8–5.01), nephrolithiasis (OR, 1.7; 95% CI, 1.04–3.04), renal failure (OR, 5.6; 95% CI, 2.7–11.4), serum total cholesterol (TC), (OR, 1.6; 95% CI, 1.0–2.8), serum creatinine (OR, 2.5; 95% CI, 1.2–5.1), increased the risk for CHD in patients with a gout.</p><p><b>.</b> The prevalence of CHD was 38.8% among individuals with gout (one-third of patients had a history of MI 29.7%). Our study showed that both TRFs of CVD and the severity of gout and a history of renal failure contribute to the development of CHD in patients with gout.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"269 - 276"},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction of the PERK-eIF2α-ATF4 Pathway in M1 Macrophages under Endoplasmic Reticulum Stress 内质网应激下诱导 M1 巨噬细胞中的 PERK-eIF2α-ATF4 通路
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924600301
O. E. Kolodeeva, O. E. Kolodeeva, D. A. Averinskaya, Yu. A. Makarova

Translation inhibition can activate two cell death pathways. The first pathway is activated by translational aberrations, the second by endoplasmic reticulum (ER) stress. In this work, the effect of ribosome-inactivating protein type II (RIP-II) viscumin on M1 macrophages derived from the THP-1 cell line was investigated. The number of modified ribosomes was evaluated by real-time PCR. Transcriptome analysis revealed that viscumin induces the ER stress activated by the PERK sensor.

翻译抑制可激活两种细胞死亡途径。第一种途径由翻译畸变激活,第二种途径由内质网(ER)应激激活。本研究调查了核糖体灭活蛋白 II 型(RIP-II)粘蛋白对源自 THP-1 细胞系的 M1 巨噬细胞的影响。实时 PCR 评估了修饰核糖体的数量。转录组分析表明,粘蛋白可诱导由 PERK 传感器激活的 ER 应激。
{"title":"Induction of the PERK-eIF2α-ATF4 Pathway in M1 Macrophages under Endoplasmic Reticulum Stress","authors":"O. E. Kolodeeva,&nbsp;O. E. Kolodeeva,&nbsp;D. A. Averinskaya,&nbsp;Yu. A. Makarova","doi":"10.1134/S1607672924600301","DOIUrl":"10.1134/S1607672924600301","url":null,"abstract":"<p>Translation inhibition can activate two cell death pathways. The first pathway is activated by translational aberrations, the second by endoplasmic reticulum (ER) stress. In this work, the effect of ribosome-inactivating protein type II (RIP-II) viscumin on M1 macrophages derived from the THP-1 cell line was investigated. The number of modified ribosomes was evaluated by real-time PCR. Transcriptome analysis revealed that viscumin induces the ER stress activated by the PERK sensor.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"264 - 268"},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis 类风湿性关节炎 ACPA 阴性和 ACPA 阳性患者的抗卡巴米蛋白抗体。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700960
D. A. Dibrov, A. S. Avdeeva, M. E. Diatroptov,  E. L. Nasonov

The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis.

. The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (n = 75) and ACPA-negative (n = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL).

. Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (p < 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (p = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (p < 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%.

In the ACPA(+) RA group, the erosion count was statistically significantly higher (p = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group.

. We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.

本研究的目的是评估氨甲酰化蛋白抗体的水平,并分析 ACPA 阴性和 ACPA 阳性变异型类风湿性关节炎患者的临床和免疫学关联。研究涉及 150 名确诊为类风湿性关节炎的患者和 25 名健康对照组患者。根据 ACPA 值的不同,招募了两组患者:ACPA阳性(75人)和ACPA阴性(75人)。通过 DAS28 指数评估 RA 活性。氨甲酰化蛋白抗体的测定采用酶联免疫吸附试验(中国蓝基因生物技术有限公司)。血清中 ACPA 的定量检测采用酶联免疫法,使用商品试剂盒(AxisShield,英国;正常上限 5.0 U/mL;Orgentec,德国;正常上限 20.0 U/mL)。RA 患者抗 CarP 中位数为 126.2 [100.83; 157.41] ng/mL,在统计学上显著高于健康对照组(88.89 [70.53; 107.75] ng/mL)(p < 0.001)。在所有RA患者中,有50人(33.3%)抗Carp阳性(ACPA(+)组22人(29.3%),ACPA(-)组28人(37.3%)),健康对照组有1名志愿者(2%)抗CarP(+)(p = 0.002)。为评估抗 CarP 对所有 RA 患者的诊断意义而进行的 ROC 分析显示,曲线下面积为 0.783 ± 0.047,95% CI:0.691-0.874(p < 0.001),临界点为 143 ng/mL,特异性为 96%,敏感性为 36.7%。在ACPA(+)RA组中,抗CarP(+)患者的侵蚀计数在统计学上明显高于抗CarP(-)患者(p = 0.044)。在 ACPA(-)RA 组中,抗 CarP 与 DAS28 之间存在微弱的直接相关性。我们研究了抗 CarP 作为辅助生物标记物在 ACPA(+)和 ACPA(-)亚型 RA 中的预测价值。与ACPA(+)抗CarP(-)患者相比,ACPA(+)抗CarP(-)患者的疾病亚型更具 "侵蚀性"。在 ACPA(-)患者中,抗 CarP 有助于识别侵蚀性更强的疾病亚型,而在 ACPA(-)患者中,抗 CarP 有助于降低血清阴性患者的比例。还需要进一步研究来确定抗 CarP 实验室诊断的最佳标准,并明确这些 ABs 作为其他风湿性疾病关节炎鉴别诊断的一部分所具有的诊断潜力。
{"title":"Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis","authors":"D. A. Dibrov,&nbsp;A. S. Avdeeva,&nbsp;M. E. Diatroptov,&nbsp; E. L. Nasonov","doi":"10.1134/S1607672924700960","DOIUrl":"10.1134/S1607672924700960","url":null,"abstract":"<p>The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis.</p><p>. The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (<i>n</i> = 75) and ACPA-negative (<i>n</i> = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL).</p><p>. Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (<i>p</i> &lt; 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (<i>p</i> = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (<i>p</i> &lt; 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%.</p><p>In the ACPA(+) RA group, the erosion count was statistically significantly higher (<i>p</i> = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group.</p><p>. We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"235 - 242"},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis 类风湿关节炎 ACPA 阴性变异型和 ACPA 阳性变异型的临床特征。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-13 DOI: 10.1134/S1607672924700996
D. A. Dibrov, A. S. Avdeeva, V. V. Rybakova, N. V. Demidova,  E. L. Nasonov

The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis.

The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices).

The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively.

In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (p < 0.05).

According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients.

Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients.

. In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.

该研究的目的是调查 ACPA 阴性和 ACPA 阳性变异型类风湿性关节炎患者的临床表现特征:研究对象包括根据 ACR/EULAR 2010 标准确诊为类风湿性关节炎(RA)的患者。根据 ACPA 值,招募了两组患者:ACPA阳性和ACPA阴性两组患者在性别、年龄、病程和治疗方面具有可比性。根据 DAS28、SDAI、CDAI 指数,对发病性质、病程和 RA 活动性进行了评估:研究涉及 79 名 ACPA 阴性变异型 RA 患者和 79 名 ACPA 阳性患者。ACPA(-)变异型患者的年龄(Me[IR](单位:岁))为52[39;62];ACPA(+)变异型患者的年龄(Me[IR](单位:岁))为54[42;62];病程(单位:月)分别为59[23;122]和48[17;84]。ACPA(+)患者的疾病活动度较高(通过 DAS 28crp、DAS 28esr、SDAI、CDAI 等指数),C 反应蛋白和红细胞沉降率的数值较高,关节疼痛和肿胀的数量较多(P < 0.05)。从受累关节的部位来看,ACPA(+)患者的关节炎多见于近端指间关节、掌指关节、腕关节和肩关节。据统计,ACPA(+)患者在检查时和病史中出现全身性 RA 表现的比例(32.9%)明显高于 ACPA(-)患者(17.7%)。在全身表现中,类风湿结节在 ACPA(+)患者中更为常见,而在 ACPA(-)患者中,神经病变、硬结和上皮炎的发病率则呈上升趋势。结论:在 ACPA(-)亚型患者中,关节损伤和炎症成分的临床表现不如 ACPA(+)明显。然而,由于表现不一、病程不太 "光明"、缺乏特征性免疫生物标志物,因此有必要对这部分患者进行长期、仔细的监测。同时,疾病的主观严重程度和强直性关节引起的功能障碍与ACPA(+)变异型RA并无不同。
{"title":"Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis","authors":"D. A. Dibrov,&nbsp;A. S. Avdeeva,&nbsp;V. V. Rybakova,&nbsp;N. V. Demidova,&nbsp; E. L. Nasonov","doi":"10.1134/S1607672924700996","DOIUrl":"10.1134/S1607672924700996","url":null,"abstract":"<p>The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis.</p><p>The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices).</p><p>The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively.</p><p>In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (<i>p</i> &lt; 0.05).</p><p>According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients.</p><p>Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients.</p><p><b>.</b> In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"243 - 249"},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Composition and Content of Fatty Acids in Muscle Tissue of the Potanin Altai Osman Oreoleuciscus potanini (Cypriniformes, Actinopterigii) from Mongolian Reservoirs 蒙古水库中的阿尔泰奥曼鲤鱼(鲤形目,动蝶科)肌肉组织中脂肪酸的组成和含量
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-01 DOI: 10.1134/S160767292470100X
Yu. Yu. Dgebuadze,  N. N. Sushchik, B. Mendsaikhan, D. Altansukh, A. Y. Emelianova,  M. I. Gladyshev

The composition of fatty acids in the muscle tissue of the unique Central Asian carp-like fish, Potanin Altai osman Oreoleuciscus potanini, was studied for the first time. The populations of these fish in the reservoirs of the semiarid zone (Durgun and Taishir) during the period of their formation are considered. It was shown that the content of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids in O. potanini corresponds to the median of this value in the order Cypriniformes. It was established that the basis of the food web of the herbivorous form of this species consists of microalgae (diatoms, Euglena and, possibly, chrysophytes), as well as bacteria. At the same time, the levels of bacterial biomarkers, 15-17BCFA and 17:0 were significantly higher in fish in the Durgun reservoir, whereas the level of EPA (diatom biomarker) in O. potanini was higher in the Taishir reservoir. The established higher values of the heavy nitrogen isotope content in the muscles of O. potanini from the Taishir reservoir are most likely associated with the yet unformed benthic communities and with the incomplete diversification of the riverine form of the Potanin Altai osman into lacustrine forms.

首次研究了中亚独特的鲤科鱼类 Potanin Altai osman Oreoleuciscus potanini 肌肉组织中的脂肪酸组成。研究考虑了半干旱地区(杜尔贡和塔希尔)水库中这些鱼类形成时期的种群数量。研究表明,O. potanini 中的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)含量与鲤形目中这一数值的中位数一致。研究结果表明,该物种草食性食物网的基础是微藻(硅藻、八角藻,可能还有菊叶藻)和细菌。同时,杜尔贡水库中鱼类的细菌生物标志物、15-17BCFA 和 17:0 的含量明显较高,而塔希尔水库中 O. potanini 的 EPA(硅藻生物标志物)含量较高。塔依什尔水库中的 O. potanini 肌肉重氮同位素含量较高,这很可能与尚未形成的底栖生物群落有关,也与波坦宁阿尔泰鄂温克人的河流形态未完全分化为湖泊形态有关。
{"title":"Composition and Content of Fatty Acids in Muscle Tissue of the Potanin Altai Osman Oreoleuciscus potanini (Cypriniformes, Actinopterigii) from Mongolian Reservoirs","authors":"Yu. Yu. Dgebuadze,&nbsp; N. N. Sushchik,&nbsp;B. Mendsaikhan,&nbsp;D. Altansukh,&nbsp;A. Y. Emelianova,&nbsp; M. I. Gladyshev","doi":"10.1134/S160767292470100X","DOIUrl":"10.1134/S160767292470100X","url":null,"abstract":"<p>The composition of fatty acids in the muscle tissue of the unique Central Asian carp-like fish, Potanin Altai osman <i>Oreoleuciscus potanini</i>, was studied for the first time. The populations of these fish in the reservoirs of the semiarid zone (Durgun and Taishir) during the period of their formation are considered. It was shown that the content of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids in <i>O. potanini</i> corresponds to the median of this value in the order Cypriniformes. It was established that the basis of the food web of the herbivorous form of this species consists of microalgae (diatoms, <i>Euglena</i> and, possibly, chrysophytes), as well as bacteria. At the same time, the levels of bacterial biomarkers, 15-17BCFA and 17:0 were significantly higher in fish in the Durgun reservoir, whereas the level of EPA (diatom biomarker) in <i>O. potanini</i> was higher in the Taishir reservoir. The established higher values of the heavy nitrogen isotope content in the muscles of <i>O. potanini</i> from the Taishir reservoir are most likely associated with the yet unformed benthic communities and with the incomplete diversification of the riverine form of the Potanin Altai osman into lacustrine forms.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"300 - 304"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of Life Cycles of Nematodes Parasitizing Woody Plants As a Result of Ecological and Phylogenetic Co-Adaptations with Hosts and Vectors 寄生于木本植物的线虫生命周期的进化是与寄主和媒介物的生态和系统发育共同适应的结果。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-01 DOI: 10.1134/S1607672924701047
A. Yu. Ryss

Fundamental aspects in the evolution of nematodes parasitizing woody plants are reviewed. (1) Nematode faunal lists of natural refugia are useful to predict the risks of opportunistic pathogens becoming true pathogens in the forest and park communities. (2) Nematode composition in natural refugia gives a chance to identify nematode antagonists of insect vectors of dangerous fungal and nematode infections, which can be potentially used as the biological agents for woody plants’ protection. (3) Dauers in the ancestors of wood-inhabiting nematodes played a role as a survival stage in the detritus decomposition succession, and they later acquired the functions of dispersal and adaptations for transmission using insect vectors. (4) When inspecting wilted trees, it is necessary to use dauers for diagnostics, as sexually mature nematodes may be absent in tree tissues. (5) Plant parasitic nematodes originated from members of the detritus food web and retained a detritivorous phase in the life cycle as a part of the propagative generation. (6) Vectors in the life cycles of plant parasitic nematodes are inherited from the ancestral detritivorous nematode associations, rather than inserted in the dixenic life cycle of the ‘nematode–fungus–plant’ association. (7) Despite the significant difference in the duration of the nematode–tree and nematode–vector phases of the life cycle, the actual parasitic nematode specificity is dual: firstly to the vector and secondly to the natural host plant (as demonstrated in phytotests excluding a vector).

综述了寄生木本植物的线虫进化的基本方面。(1) 天然避难所的线虫动物清单有助于预测机会性病原体成为森林和公园群落中真正病原体的风险。(2) 天然庇护所中的线虫组成为确定危险真菌和线虫感染的昆虫载体的线虫拮抗剂提供了机会,这些拮抗剂可用作木本植物保护的生物制剂。(3)栖息于木本植物的线虫祖先中的 "道尔"(Dauer)在残渣分解演替中扮演着生存阶段的角色,后来获得了传播功能和利用昆虫媒介传播的适应性。(4) 在检查枯萎的树木时,有必要使用道尔进行诊断,因为树木组织中可能没有性成熟的线虫。(5) 植物寄生线虫起源于碎屑食物网的成员,在生命周期中保留了碎屑阶段,作为繁殖世代的一部分。(6) 植物寄生线虫生命周期中的媒介物是从祖先的食腐线虫协会继承而来,而不是插入 "线虫-真菌-植物 "协会的二生生命周期中。(7) 尽管线虫-树木和线虫-载体的生命周期在持续时间上存在显著差异,但实际的寄生线虫特异性是双重的:首先是对载体的特异性,其次是对天然寄主植物的特异性(这一点已在不包括载体的植物试验中得到证明)。
{"title":"Evolution of Life Cycles of Nematodes Parasitizing Woody Plants As a Result of Ecological and Phylogenetic Co-Adaptations with Hosts and Vectors","authors":"A. Yu. Ryss","doi":"10.1134/S1607672924701047","DOIUrl":"10.1134/S1607672924701047","url":null,"abstract":"<p>Fundamental aspects in the evolution of nematodes parasitizing woody plants are reviewed. (1) Nematode faunal lists of natural refugia are useful to predict the risks of opportunistic pathogens becoming true pathogens in the forest and park communities. (2) Nematode composition in natural refugia gives a chance to identify nematode antagonists of insect vectors of dangerous fungal and nematode infections, which can be potentially used as the biological agents for woody plants’ protection. (3) Dauers in the ancestors of wood-inhabiting nematodes played a role as a survival stage in the detritus decomposition succession, and they later acquired the functions of dispersal and adaptations for transmission using insect vectors. (4) When inspecting wilted trees, it is necessary to use dauers for diagnostics, as sexually mature nematodes may be absent in tree tissues. (5) Plant parasitic nematodes originated from members of the detritus food web and retained a detritivorous phase in the life cycle as a part of the propagative generation. (6) Vectors in the life cycles of plant parasitic nematodes are inherited from the ancestral detritivorous nematode associations, rather than inserted in the dixenic life cycle of the ‘nematode–fungus–plant’ association. (7) Despite the significant difference in the duration of the nematode–tree and nematode–vector phases of the life cycle, the actual parasitic nematode specificity is dual: firstly to the vector and secondly to the natural host plant (as demonstrated in phytotests excluding a vector).</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"325 - 345"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconstruction of Derogenes varicus Miracidium (Digenea: Derogenidae): First Ultrastructural Description of Spines on the Surface of Hemiurata Larvae Derogenes varicus Miracidium(Digenea:Derogenidae)的重建:首次从超微结构角度描述半知更虫幼虫表面的刺。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-01 DOI: 10.1134/S1607672924701059
P. A. Smirnov, D. Yu. Krupenko

We performed a detailed ultrastructural reconstruction of the “passive” miracidium of Derogenes varicus Muller, 1784 , a species from the Hemiurata group. The miracidium is highly miniaturized and simplified in comparison with the “active” miracidia. For the first time we elucidated the nature of the spines on the surface of the hemiuroid larva: they are derivatives of the epithelial plates. The anterior end of the larva is equipped with three epithelial plates that bear both spines and cilia. The major part of the miracidial surface is formed by the tegument. The nervous and excretory systems of the D. varicus miracidium are extremely reduced. Single undifferentiated cell comprises the germinal material of the miracidium. We discuss the trends of evolution of hemiuroid miracidia that are associated with the transition to passive strategy of infection.

我们对半月蝇属物种 Derogenes varicus Muller, 1784 的 "被动 "虹膜进行了详细的超微结构重建。与 "主动 "虹膜相比,虹膜高度微型化和简化。我们首次阐明了半知虫幼虫表面棘刺的性质:它们是上皮板的衍生物。幼虫的前端有三个上皮板,上皮板上有棘刺和纤毛。蜃蛛表面的主要部分由皮膜构成。变种栉水母的神经系统和排泄系统非常弱小。单个未分化细胞构成了栉水母的生殖物质。我们讨论了半uroid miracidia 的进化趋势,这与向被动感染策略的过渡有关。
{"title":"Reconstruction of Derogenes varicus Miracidium (Digenea: Derogenidae): First Ultrastructural Description of Spines on the Surface of Hemiurata Larvae","authors":"P. A. Smirnov,&nbsp;D. Yu. Krupenko","doi":"10.1134/S1607672924701059","DOIUrl":"10.1134/S1607672924701059","url":null,"abstract":"<p>We performed a detailed ultrastructural reconstruction of the “passive” miracidium of <i>Derogenes varicus</i> Muller, 1784 , a species from the Hemiurata group. The miracidium is highly miniaturized and simplified in comparison with the “active” miracidia. For the first time we elucidated the nature of the spines on the surface of the hemiuroid larva: they are derivatives of the epithelial plates. The anterior end of the larva is equipped with three epithelial plates that bear both spines and cilia. The major part of the miracidial surface is formed by the tegument. The nervous and excretory systems of the <i>D. varicus</i> miracidium are extremely reduced. Single undifferentiated cell comprises the germinal material of the miracidium. We discuss the trends of evolution of hemiuroid miracidia that are associated with the transition to passive strategy of infection.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"346 - 354"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic 在SARS-CoV-2大流行期间,对类风湿关节炎患者从抗B细胞疗法转为奥洛珠单抗疗法的疗效和安全性进行的一项为期12周的开放标签、非干预性研究的结果。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-01 DOI: 10.1134/S1607672924701060
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Y. D. Kurochkina, Y. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev
<p>The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality. At the same time, the analysis of real clinical practice data dictated the need to establish a number of restrictions on the use of certain classes of biologics and to search for alternative therapy programs to maintain control over disease activity.</p><p><b>Purpose of the study.</b> The purpose of the study was to evaluate the efficacy and safety of the drug Artlegia® (olokizumab), solution for subcutaneous injection, 160 mg/ml-0.4 ml, manufactured by R-Pharm JSC, Russia) for the treatment of patients with rheumatoid arthritis in real clinical practice after switching with rituximab during the COVID-19 pandemic.</p><p><b>Materials and methods.</b> The study included 14 patients with a confirmed diagnosis of rheumatoid arthritis (RA), who were previously on rituximab therapy at a dose of 1000–500 mg twice with an interval of 2 weeks, who received at least one course of therapy with this drug. As RA worsened, patients were switched to olokizumab against the background of standard DMARDs. On weeks 0, 4, 8, and 12 after the switch, the severity of pain was assessed on the VAS scale, the number of tender and swollen joints (TJC28 and SJC28), the level of acute-phase inflammation markers, the DAS28 (disease activity score), ESR, CRP, CDAI (clinical activity index), and the functional state index HAQ (Health Assessment Questionnaire) were determined, as well as the safety profile of therapy was assessed.</p><p><b>Results.</b> Data analysis was performed using median values (Me) were used for data analysis. A significant decrease in TJC28 was detected after 8 and 12 weeks of treatment with olokizumab (Artlegia®) (Me baseline = 10, Me 8 weeks = 4, Me 12 weeks = 4, <i>p</i> < 0.05) and a decrease in TSC28 was detected after 4, 8, and 12 weeks of treatment (Me baseline = 9, Me 4 weeks = 3.5, Me 8 weeks = 2.5, Me 12 weeks = 2.0, <i>p</i> < 0.05). Laboratory markers of inflammation showed a decrease in CRP and ESR levels after 4 weeks of treatment (CRP: Me4 weeks = 21, Me4 weeks = 1, <i>p</i> < 0.05, ESR: Mesno = 31, Me4 weeks = 7, <i>p</i> < 0.05). Positive dynamics persisted on 8 and 12 weeks (CRP: Me 8 weeks = 1, Me 12 weeks = 0; ESR: Me 8 weeks = 4, Me 12 weeks = 5). The level of CRP by week 4 became within the normal range, regardless of the initial values. All activity indices improved from week 4 in each evaluation period compared to baseline: DAS28-ESR: Me baseline = 5.52,
摘要-COVID-19大流行极大地改变了人们对免疫炎症性风湿病(IRD)疗法安全性的认识。这主要是由于一些基本的改善病情抗风湿药物(DMARDs)和基因工程生物药物(生物 DMARDs 或生物制剂)对新型冠状病毒感染的过程和结果产生了负面影响。一些研究表明,抗 B 细胞疗法(利妥昔单抗)会在统计学上显著增加发生严重 COVID-19 的风险,并增加死亡率。与此同时,对实际临床实践数据的分析决定了有必要对某些类别生物制剂的使用制定一系列限制,并寻找替代治疗方案,以保持对疾病活动的控制:研究目的:该研究旨在评估Artlegia®(奥洛珠单抗)药物(皮下注射溶液,160毫克/毫升-0.4毫升,俄罗斯R-Pharm股份公司生产)在COVID-19大流行期间换用利妥昔单抗后在实际临床实践中治疗类风湿性关节炎患者的疗效和安全性:研究对象包括 14 名确诊为类风湿性关节炎(RA)的患者,这些患者曾接受过利妥昔单抗治疗,剂量为 1000-500 毫克,两次间隔 2 周,至少接受过一个疗程的治疗。随着RA病情恶化,患者在使用标准DMARDs的基础上改用olokizumab。在换药后的第0、4、8和12周,用VAS量表评估疼痛的严重程度、关节触痛和肿胀的数量(TJC28和SJC28)、急性期炎症标志物的水平、DAS28(疾病活动评分)、血沉、CRP、CDAI(临床活动指数)和功能状态指数HAQ(健康评估问卷),并评估治疗的安全性:数据分析采用中位值(Me)。使用奥洛单抗(Artlegia®)治疗8周和12周后,发现TJC28明显下降(Me基线=10,Me 8周=4,Me 12周=4,P<0.05),治疗4周、8周和12周后,发现TSC28下降(Me基线=9,Me 4周=3.5,Me 8周=2.5,Me 12周=2.0,P<0.05)。实验室炎症指标显示,治疗 4 周后 CRP 和 ESR 水平下降(CRP:Me4 周 = 21,Me4 周 = 1,p < 0.05;ESR:Mesno = 31,Me4 周 = 7,p < 0.05)。在第 8 周和第 12 周,积极的动态变化持续存在(CRP:Me 8 周 = 1,Me 12 周 = 0;ESR:Me 8 周 = 4,Me 12 周 = 5)。无论初始值如何,第 4 周的 CRP 水平都在正常范围内。与基线相比,每个评估期的所有活动指数从第 4 周开始都有所改善:DAS28-ESR:我的基线 = 5.52,我的第 4 周 = 3.59,我的第 8 周 = 3.33,我的第 12 周 = 3.22,P < 0.05;DAS28CRP:我的基线 = 5.39,我的第 4 周 = 3.71,我的第 8 周 = 3.35,我的第 12 周 = 3.45,P < 0.05;CDAI:我的基线 = 28.5,我的第 4 周 = 18.0,我的第 8 周 = 16.5,我的第 12 周 = 16.0,P < 0.05。到第 8 周时,所有患者的疼痛都有所减轻(VAS 量表)。根据 HAQ 指数,患者的功能状态仅在研究第 12 周时才出现显著下降:基线 = 1.62,12 周 = 1.31,P < 0.05:研究发现,在 COVID-19 大流行期间,从利妥昔单抗转用奥洛珠单抗是有效和安全的。
{"title":"Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic","authors":"A. A. Akimova,&nbsp;N. E. Banshchikova,&nbsp;A. E. Sizikov,&nbsp;A. A. Mullagaliev,&nbsp;E. A. Letyagina,&nbsp;N. A. Ilina,&nbsp;Y. D. Kurochkina,&nbsp;Y. B. Ubshaeva,&nbsp;V. O. Omelchenko,&nbsp;O. A. Chumasova,&nbsp;N. S. Shkaruba,&nbsp;M. A. Korolev","doi":"10.1134/S1607672924701060","DOIUrl":"10.1134/S1607672924701060","url":null,"abstract":"&lt;p&gt;The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality. At the same time, the analysis of real clinical practice data dictated the need to establish a number of restrictions on the use of certain classes of biologics and to search for alternative therapy programs to maintain control over disease activity.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Purpose of the study.&lt;/b&gt; The purpose of the study was to evaluate the efficacy and safety of the drug Artlegia® (olokizumab), solution for subcutaneous injection, 160 mg/ml-0.4 ml, manufactured by R-Pharm JSC, Russia) for the treatment of patients with rheumatoid arthritis in real clinical practice after switching with rituximab during the COVID-19 pandemic.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Materials and methods.&lt;/b&gt; The study included 14 patients with a confirmed diagnosis of rheumatoid arthritis (RA), who were previously on rituximab therapy at a dose of 1000–500 mg twice with an interval of 2 weeks, who received at least one course of therapy with this drug. As RA worsened, patients were switched to olokizumab against the background of standard DMARDs. On weeks 0, 4, 8, and 12 after the switch, the severity of pain was assessed on the VAS scale, the number of tender and swollen joints (TJC28 and SJC28), the level of acute-phase inflammation markers, the DAS28 (disease activity score), ESR, CRP, CDAI (clinical activity index), and the functional state index HAQ (Health Assessment Questionnaire) were determined, as well as the safety profile of therapy was assessed.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results.&lt;/b&gt; Data analysis was performed using median values (Me) were used for data analysis. A significant decrease in TJC28 was detected after 8 and 12 weeks of treatment with olokizumab (Artlegia®) (Me baseline = 10, Me 8 weeks = 4, Me 12 weeks = 4, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) and a decrease in TSC28 was detected after 4, 8, and 12 weeks of treatment (Me baseline = 9, Me 4 weeks = 3.5, Me 8 weeks = 2.5, Me 12 weeks = 2.0, &lt;i&gt;p&lt;/i&gt; &lt; 0.05). Laboratory markers of inflammation showed a decrease in CRP and ESR levels after 4 weeks of treatment (CRP: Me4 weeks = 21, Me4 weeks = 1, &lt;i&gt;p&lt;/i&gt; &lt; 0.05, ESR: Mesno = 31, Me4 weeks = 7, &lt;i&gt;p&lt;/i&gt; &lt; 0.05). Positive dynamics persisted on 8 and 12 weeks (CRP: Me 8 weeks = 1, Me 12 weeks = 0; ESR: Me 8 weeks = 4, Me 12 weeks = 5). The level of CRP by week 4 became within the normal range, regardless of the initial values. All activity indices improved from week 4 in each evaluation period compared to baseline: DAS28-ESR: Me baseline = 5.52, ","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"291 - 299"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organization of the Nuclei in the Tegument of Some Palaeacanthocephala and Archiacanthocephala 一些古棘皮动物和大棘皮动物皮层中的细胞核组织。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-07-01 DOI: 10.1134/S1607672924701023
V. P. Nikishin, D. V. Ponomarev

The giant tegument nuclei of the acanthocephalans of the classes Archiacanthocephala and Palaeacanthocephala are fragmented at the final stage of cystacanthus formation in the intermediate host, but remain connected with each other during later life. It can be assumed that the fragments of each giant tegument nucleus are united with each other to form an independent network that ensures the vital activity of the tegument, the volume of which increases many times during the period of intensive growth of the parasite in the definitive host.

在中间宿主体内形成囊尾蚴的最后阶段,棘尾虫类(Archiacanthocephala)和古棘尾虫类(Palaeacanthocephala)的巨型鞘核会碎裂,但在以后的生活中仍彼此相连。可以推测,每个巨型被膜核的碎片相互连接,形成一个独立的网络,确保被膜的生命活动,在寄生虫在最终宿主体内密集生长期间,被膜的体积会增加许多倍。
{"title":"Organization of the Nuclei in the Tegument of Some Palaeacanthocephala and Archiacanthocephala","authors":"V. P. Nikishin,&nbsp;D. V. Ponomarev","doi":"10.1134/S1607672924701023","DOIUrl":"10.1134/S1607672924701023","url":null,"abstract":"<p>The giant tegument nuclei of the acanthocephalans of the classes Archiacanthocephala and Palaeacanthocephala are fragmented at the final stage of cystacanthus formation in the intermediate host, but remain connected with each other during later life. It can be assumed that the fragments of each giant tegument nucleus are united with each other to form an independent network that ensures the vital activity of the tegument, the volume of which increases many times during the period of intensive growth of the parasite in the definitive host.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"309 - 312"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Doklady Biochemistry and Biophysics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1